Imatinib Tad

Imatinib, the active ingredient in Imatinib Tad, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor and other KIT‑positive tumors in adult patients.

GNH USA supplies Imatinib Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase signaling. It is employed in several oncology indications.

- Chronic myeloid leukemia (CML): controls disease progression and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): reduces tumor growth in KIT‑mutated disease. - Dermatofibrosarcoma protuberans (DFSP): shrinks lesions driven by PDGFR. - Other KIT‑positive tumors: provides targeted inhibition of oncogenic signaling.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially of the ankles. - Muscle cramps: intermittent, often related to electrolyte shifts. - Fatigue: generalized tiredness. - Diarrhea: loose stools, usually self‑limiting. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Myelosuppression: neutropenia, anemia, thrombocytopenia. - Cardiotoxicity: left ventricular dysfunction or heart failure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary arterial hypertension: rare increase in pulmonary pressure. - Renal impairment: acute kidney injury in susceptible patients.

When prescribing Imatinib, clinicians should consider several safety measures.

- Baseline laboratory testing: obtain complete blood count, liver and renal function before initiation. - Monitor cardiac function: assess ejection fraction in patients with pre‑existing heart disease. - Assess for drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks. - Patient counseling: advise on signs of infection, bleeding or severe skin reactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Imatinib may interact with several agents that alter its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and risk of adverse events. - Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Phenytoin: may increase risk of myelosuppression; check blood counts regularly. - Digoxin: potential increase in serum levels; assess renal function and adjust dose if needed.